The potential of fixed-duration BTKis and using MRD to guide treatment discontinuation in WM
Neil Berinstein, MD, Sunnybrook Odette Cancer Centre, Toronto, Canada, discusses the debate between fixed-duration and continuous BTK inhibitor (BTKi) treatment in Waldenström’s macroglobulinemia and other malignancies. He advocates for fixed-duration therapy due to the issue of cumulative toxicities associated with continuous administration of BTKis and suggests that measurable residual disease (MRD) could be used to guide treatment discontinuation. This interview took place at the 12th International Workshop on Waldenström's Macroglobulinemia (IWWM-12) in Prague, Czech Republic.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
Watch video The potential of fixed-duration BTKis and using MRD to guide treatment discontinuation in WM online without registration, duration hours minute second in high quality. This video was added by user VJHemOnc – Video Journal of Hematology & HemOnc 24 October 2024, don't forget to share it with your friends and acquaintances, it has been viewed on our site 120 once and liked it 1 people.